Skip to main content
. 2019 Feb 21;8(2):190. doi: 10.3390/cells8020190

Table 2.

mTOR inhibitors used alone or in association in B-ALL.

Drug/Cells Drug Target Reported Synergism Clinical Trials Reference(s)
Rapamycin
(Sirolimus)
(Ph+ B-ALL, Ph− B-ALL, Ph-like B-ALL)		 mTORC1

  • Imatinib mesylate

  • Daunorubicin

  • Focal adhesion kinase (FAK) inhibitor

  • Methotrexate

  • 6-mercaptopurine

 NCT01184885
NCT00792948 		[80,82,154,155,171]
CCI-779
(Temsirolimus)
(Ph− B-ALL)		 mTORC1 - NCT01614197
NCT01403415 		[80,81,82,96,144,182]
RAD001
(Everolimus)
(Ph+ B-ALL, Ph− B-ALL)		 mTORC1

  • Vincristine

  • Bortezomib

  • MK2206

  • LEE-01

  • (CDK4/6 inhibitor)

  • Glucocorticoids

 NCT01523977 [5,75,80,82,89,96,176,177,178,179,180,181,183]
PI-103
(Ph+ B-ALL)		 PI3K/mTOR Imatinib - [6,10,77,127,148]
PKI-587
(Gedatolisib)
(Ph+ B-ALL, Ph− B-ALL, Ph-like B-ALL)		 PI3K/mTOR - - [6,76,77,136]
BEZ235
(Ph+ B-ALL, Ph− B-ALL)		 PI3K/mTOR

  • Nilotinib

  • GX15-070

  • Methotrexate

  • 6-mercaptopurine

 - [6,10,84,95,162,181]
BGT226
(Ph− B-ALL)		 PI3K/mTOR - - [8,100,101,102]
PP-242
(Ph+ B-ALL)		 mTORC1/mTORC2 - - [80,85,150]
Torin-2
(B-pre-ALL)		 mTORC1/mTORC2 MK2206 - [80,85,180]
MLN0128
(Ph+ B-ALL, Ph− B-ALL)		 mTORC1/mTORC2 Dasatinib - [80,85,164]